Q - Adaptive Biotechnologies
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $43,163 | $47,920 |
| Short-term marketable securities (amortized cost of $154,672 and $174,186, respectively) | 154,710 | 174,374 |
| Accounts receivable, net | 44,285 | 41,731 |
| Inventory, net | 8,403 | 8,440 |
| Prepaid expenses and other current assets | 11,295 | 11,287 |
| Total current assets | 261,856 | 283,752 |
| Long-term assets | ||
| Property and equipment, net | 41,055 | 48,616 |
| Operating lease right-of-use assets | 43,338 | 45,767 |
| Long-term marketable securities (amortized cost of $24,065 and $33,682, respectively) | 24,100 | 33,660 |
| Restricted cash | 2,720 | 2,897 |
| Intangible assets, net | 2,583 | 3,425 |
| Goodwill | 118,972 | 118,972 |
| Other assets | 2,013 | 2,287 |
| Total assets | $496,637 | $539,376 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $6,908 | $7,265 |
| Accrued liabilities | 7,205 | 8,157 |
| Accrued compensation and benefits | 9,700 | 15,838 |
| Current portion of operating lease liabilities | 9,957 | 10,239 |
| Current portion of deferred revenue | 55,301 | 55,689 |
| Current portion of revenue interest liability, net | 3,070 | 865 |
| Total current liabilities | 92,141 | 98,053 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 74,413 | 79,148 |
| Deferred revenue, less current portion | 20,032 | 27,256 |
| Revenue interest liability, net, less current portion | 130,495 | 132,414 |
| Other long-term liabilities | 20 | 20 |
| Total liabilities | 317,101 | 336,891 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity | ||
| Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2025 and December 31, 2024; no shares issued and outstanding at June 30, 2025 and December 31, 2024 | — | — |
| Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2025 and December 31, 2024; 152,234,772 and 147,773,744 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 15 | 14 |
| Additional paid-in capital | 1,538,919 | 1,506,353 |
| Accumulated other comprehensive gain | 73 | 166 |
| Accumulated deficit | (1,359,290) | (1,303,824) |
| Total Adaptive Biotechnologies Corporation shareholders’ equity | 179,717 | 202,709 |
| Noncontrolling interest | (181) | (224) |
| Total shareholders’ equity | 179,536 | 202,485 |
| Total liabilities and shareholders’ equity | $496,637 | $539,376 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.